All rights reserved. No reuse allowed without permission.

1 2	Genomic predictors of response to antidepressants in Major depressive disorder (MDD): A GWAS-Based Study on Indian cohort
3	
4	Isha Goel <sup>1,2</sup> , Gagan Hans <sup>1</sup> , Nand Kumar <sup>1,*</sup> , Subhradip Karmakar <sup>2,*</sup>
5	
6 7 8 9	<ol> <li>Department of Psychiatry, All India Institute of Medical Sciences, New Delhi 110029, India</li> <li>Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India</li> <li>* Corresponding Authors</li> </ol>
10 11	Abstract
12	
13 14	Background: Major depressive disorder (MDD) affects a significant portion of the population, with approximately 70% of patients not achieving adequate remission using anti-depressant

14 with approximately 70% of patients not achieving adequate remission using anti-depressant 15 monotherapy, a condition known as inadequate treatment response (ITR). In the Indian population, 16 few studies have explored the genetic associations of this response, and those that exist are 17 underpowered. This study aims to identify single nucleotide variations associated with ITR in the 18 Indian population. The goal is to develop a population-specific gene panel that can identify 19 subjects at risk for ITR, allowing alternative treatment modalities.

20

21 Methods: Subjects satisfying inclusion-exclusion criteria were enrolled for the study following 22 institutional ethical approval. We recruited 120 subjects with MDD and assessed their response to 23 monotherapy (Escitalopram) using the Hamilton Depression Rating Scale (HAMD) before and 4-24 6 weeks after medication. Responders (n=45) and non-responders (n=75) were genotyped using 25 the Infinium Global Screening SNP-Array-24 v3.0. A genome-wide association study (GWAS) 26 was performed to identify SNPs associated with ITR.

28 Results: Twelve lead-significant SNPs with a threshold of < 1E-05 were identified, suggesting an 29 association with ITR. Among these, four SNPs were located in the intronic/regulatory regions of 30 the genes *LRSAM1*, *EFCAB2*, *TRIM56* and *ZNF17*. The remaining eight SNPs were near genes 31 *ALDH1A2*, *LIPC*, *MYOCD*, *SPRY2*, *ANKRD18B*, *CCDC54*, *TNS3*, *ANKRD46*, and *FCRL2*. These 32 genes are involved in critical functions related to cell signalling, immune response, 33 neurodevelopment, regulating intracellular levels, and transcription factor binding.

34

35 Conclusions: Our study identified several novel SNPs that may be associated with ITR in MDD 36 patients, reported for the first time in an Indian cohort. Further investigations are underway to 37 determine their clinical significance and potential to be used for screening individuals responding 38 to drug interventions as user-friendly gene panels.

39

## 40 Keywords

41 Depression, Drug response, Personalized treatment, Genome-wide association study, Selective 42 serotonin reuptake inhibitors

All rights reserved. No reuse allowed without permission.

## 43 1. Introduction

#### 44

45 Unipolar depression, also known as Major Depressive Disorder (MDD), is among the leading 46 causes of disability worldwide, ranking fourth in terms of disease burden and accounting for 46 47 million disability-adjusted life-years (DALYs) in 2021. According to the Global Burden of 48 Disease Study 2021, depression is the fifth leading cause of disability in India, as measured by 49 DALYs. The prevalence of depressive disorders increased from 3.745 cases per million in 2019 50 to 4.418 cases per million in 2021, with Major Depressive Disorder (MDD) alone contributing to 51 over 70% of these cases, affecting nearly 45.4 million individuals in 2021 (Global Burden of 52 Disease Collaborative Network, 2024). MDD affects individuals across all genders, ages, and 53 social backgrounds. MDD is characterized by persistent sadness, loss of interest in activities, and 54 a range of emotional and physical issues, often leading to suicidal thoughts (WHO, 2023). 55 Symptoms of MDD can vary widely among individuals. First-line antidepressant monotherapy 56 prescribed includes Selective Serotonin Reuptake Inhibitors (SSRIs) such as citalopram and 57 escitalopram, and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like duloxetine and 58 venlafaxine (Johnson CF et al., 2022). Despite their widespread use, the chronic and episodic 59 nature of MDD, combined with poor psychosocial functioning, significantly contributes to the 60 global economic burden. While medications and psychotherapy are effective for many, 61 approximately 30-50% of depression patients do not achieve sufficient symptom relief with 62 monotherapy, a condition known as inadequate treatment response (ITR). The situation is 63 particularly alarming in India, where more than 70% of patients experience inadequate treatment 64 response (Rafeyan R., et al., 2020; Arvind BA., et al., 2019). 65



#### 66 67

68 Figure 1. Graph showing the numbers of disability-adjusted life-years (DALYs) due to major 69 depressive disorder in both the global and Indian contexts from 1990 to 2021. (Data and figure 70 acquired from Global Burden of Disease Collaborative Network, 2024)

71

72 One of the critical challenges in managing MDD is its multifaceted nature, which arises from 73 diverse causes, coupled with our limited understanding of its pathogenic mechanisms. Apart from 74 environmental influences like stress and trauma, genomic factors play a crucial role in the 75 development of depression. Research indicates that depression can be hereditary, with specific 76 genes involved in neurotransmitter regulation, such as serotonin, linked to a higher risk (Sullivan 77 et al., 2000). Additionally, genes related to neuroplasticity (e.g., *BDNF*), the immune system (e.g.,

All rights reserved. No reuse allowed without permission.

78 *SPP1*), and the stress response (e.g., 5-*HTTLPR*) contribute significantly to the complexity of 79 depression. (Sforzini, L., et al., 2024; Marlene et al., 2023; Caspi, A. et al., 2003). Variants in these 80 genes can predispose individuals to depression and, importantly, influence how they respond to 81 antidepressants. The National Institute of Mental Health (NIMH) conducted the sequenced 82 Treatment Alternatives to Relieve Depression (STARD) study\*, which identified genetic markers 83 associated with the effectiveness of antidepressant treatments helping to tailor personalized 84 therapeutic approaches (Laje G., et al., 2009). Table 1 provides a list of genetic variants that have 85 been associated with the response to antidepressant therapy in STARD\* study and few others 86 (Francis J. et al., 2006; Lemonde S. et al., 2004; Hong CJ., et al., 2006; Villafuerte SM., et al., 87 2009; Kato M., et al., 2009; Paddock S, et al., 2007). The genetic variants identified in the 88 STARD\* study were primarily based on a population in the United States (Caucasian, Black, and 89 Hispanic individuals), which may not fully represent the genetic diversity found in the Indian 90 population. Due to significant genetic differences and unique genetic variants in the Indian 91 population, the applicability of these findings may vary.

Gene	Genome build	Nucleotide Change	Region	rsID
	(GRCh38)			
SLC6A4	chr17:30221317-	Stin2.9, Stin2.10	SLC6A4: intronic VNTR	STin2
	30221615	and Stin2.12 (9, 10	polymorphism	
		or 12 copies of a		
		16–17 bp repeat)		
SLC6A4	chr17:30237299	A>G (l/s allele)	SLC6A4 : 2KB Upstream Variant	rs4795541
SLC6A4	chr17:30237328	T>C / T>G	SLC6A4 : 2KB Upstream Variant	rs25531
HTR1A	chr5:63955024	T>G	-	rs1364043
HTR1A	chr5:63962738	C>A / C>G	HTR1A : 2KB Upstream Variant	rs6295
HTR1B	chr6:77463275	G>A / G>C / G>T	HTR1B : Synonymous Variant	rs6298
HTR2A	chr13:46837850	A>C / A>G / A>T	HTR2A : Intron Variant	rs7997012
HTR2A	chr13:46859220	C>A / C>G / C>T	HTR2A : Intron Variant	rs9316233
HTR2A	chr13:46847701	C>T	HTR2A : Intron Variant	rs1923884
ABCB1	chr7:87531245	A>G	ABCB1 : Intron Variant	rs2032583
DTNBP1	chr6:15650901	G>A	DTNBP1 : Intron Variant	rs760761
GRIK4	chr11:120792654	T>C	GRIK4 : Intron Variant	rs1954787
TPH2	chr12:71938143	G>A / G>T	TPH2 : 2KB Upstream Variant	rs4570625
DAOA	chr13:105489886	C>A / C>T	DAOA : Synonymous Variant	rs778294
DISC1	chr1:231818355	C>T	DISC1 : Missense Variant	rs6675281
DISC1	chr1:231827745	C>A / C>T	DISC1 : Intron Variant	rs1000731
FKBP5	chr6:35702206	A>C / A>G / A>T	FKBP5 : Intron Variant	rs4713916
KCNK2	chr1:215000495	C>T	LOC124904510 : Intron Variant	rs2841616
KCNK2	chr1:215239563	G>A / G>C	KCNK2 : Downstream Variant	rs7549184
KCNK2	chr1:215246328	G>A / G>C / G>T	KCNK2 : Downstream Variant	rs10494996
KCNK2	chr1:215017904	G>C / G>T	KCNK2 : Intron Variant	rs2841608
KCNK2	chr1:215077884	G>A/G>C	KCNK2 : Intron Variant	rs12136349
KCNK2	chr1:215152892	G>A / G>T	KCNK2 : Intron Variant	rs10779646

92

93 Table 1: Table listing the details of the variants reported in literature to be associated with SSRI-94 treatment response.

95

96 This study aims to address this critical issue within the Indian population, where genetic 97 associations with treatment response have been minimally explored and existing studies lack

perpetuity. All rights reserved. No reuse allowed without permission.

98 sufficient power. By leveraging a genome-wide association study (GWAS), this research seeks to 99 identify single nucleotide polymorphisms (SNPs) associated with ITR in Indian patients, paving 100 the way for personalized treatment strategies. Building on this, our study will conduct a 101 retrospective genotypic analysis of depressed patients treated at AIIMS clinics. By comparing 102 patients requiring multi-drug therapy to those responding to monotherapy, we aim to validate 103 reported proprietary markers and discover new ones, enhancing the genetic panel for predicting 104 treatment response. This approach promises to improve clinical outcomes through earlier and 105 more accurate identification of patients at risk for ITR, ultimately guiding more effective and 106 individualized treatment plans.

107

## 108 2. Materials and methods

## 109 2.1 Subjects

The study was conducted at the Department of Biochemistry in collaboration with the 110 Department of Psychiatry at the All-India Institute of Medical Sciences (AIIMS), New Delhi, 111 India, from November 2022 to June 2024. Subjects presenting at the psychiatric outpatient 112 department with symptoms of depressive disorder were assessed based on specific inclusion 113 and exclusion criteria. Participants aged 18-65 years, who provided informed consent, and had 114 non-psychotic major depressive disorder (DSM-V), HAMD scores ≥17, and no history of 115 electroconvulsive therapy (ECT) were included. Those recommended for monotherapy 116 (Escitalopram) treatment or already on multiple antidepressants due to non-response to 117 118 escitalopram were further evaluated.

119

120 Exclusion criteria included major comorbidities such as cancer, surgery, heart disease, and 121 known or suspected pregnancy during the study period. Subjects unwilling to provide consent were also excluded. Detailed patient information was recorded in both physical files and 122 electronic documents, encompassing the patient information sheet, informed consent form, 123 referral form with socio-demographic details, medical history, primary clinical diagnosis, and 124 medication information. Depression severity was assessed using the 17-item HAMD scale 125 through structured interviews. 126

127

To determine responders and non-responders to antidepressant treatment, the severity of 128 patients' depression was evaluated twice using the aforementioned scales at two time points. 129 The first assessment was conducted on the day of patient enrolment, with those having a 130 131 HAMD score  $\geq$ 17 proceeding to further evaluation and blood collection (Evaluation I). Blood samples (4-5 ml) were drawn from consenting patients by an experienced practitioner and 132 stored in sterilized EDTA vials. Patients were re-evaluated for depression severity after 4-6 133 134 weeks of antidepressant treatment using the HAMD scale (Evaluation II). A reduction in HAMD score of  $\geq$ 50% categorized patients as responders, while those failing to meet this 135 criterion were classified as non-responders. Patients already on multiple antidepressant 136 137 therapies due to non-response to escitalopram were classified as non-responders to monotherapy. 138

139

All rights reserved. No reuse allowed without permission.





141 Figure 2: Work flow of sampling with details of Inclusion/Exclusion criteria and Evaluation

142 metrics for the stratification of patients into responders and non-responder group.

143

## 144 2.2 Sample preparation

145 Blood samples collected at the OPD were immediately sent to the molecular lab in the

146 Department of Biochemistry for DNA isolation. Using a genomic DNA extraction kit (Qiagen

147 QIAamp Blood Midi-Kit – Catalogue no. 51185), genomic DNA (gDNA) was isolated from

the blood following the standard kit protocol. The quality and quantity of the isolated gDNA

149 were assessed using a spectrophotometer (Nano Drop Technologies, Wilmington, DE, USA)

and gel electrophoresis. A DNA sample with a concentration of 100 ng/ $\mu$ L and an OD value

151 (260/280 ratio) of approximately 1.8 was considered acceptable in terms of quality.

Subsequently, 2µg of purified gDNA was used for genotyping with the Illumina Infinium Global Screening BeadChip Array v3.0 (Illumina, San Diego, CA, USA). This array enables the genotyping of over 600,000 highly optimized multi-ethnic, curated clinical variants (based based on ClinVar, NHGRI-EBI and PharmGKB databases) spanning both coding and non-

156 coding regions of the human genome. The genotyping data was generated in the form of .idat

157 files, which were then analysed using Genome Studio 2.0.

## 158 2.3 Quality Control

Raw genotyping data files (.dat files) generated from the Illumina GSA bead-chip array were 159 imported into GenomeStudio (v2.0) software (GenomeStudio Software (illumina.com)) using 160 the Illumina hg38 manifest file and sample information sheet. SNP calls were generated and 161 clustered, followed by quality control and filtering based on call rates, strand orientation, and 162 gender estimation. Metadata was enriched with phenotypes of interest, and the cleaned data 163 was exported into PLINK format for further processing. Using PLINK v1.9, the genotyping 164 data underwent quality control procedures, including assessments of SNP and individual 165 missingness, minor allele frequency, gender correction, heterozygosity, relatedness, and 166 Hardy-Weinberg equilibrium (HWE) parameters. Highly heterozygous individuals, 167 duplicates, closely related individuals, and SNPs in build-specific high linkage disequilibrium 168 (LD) regions were removed. 169

## 170

## 171 2.4 Population Stratification and Imputation

The LD-pruned data was then checked for outliers using multidimensional scaling (MDS) 172

analysis based on population stratification methodology, referencing population data from the 173 1000 Genomes Project phase 3. Outliers were identified using component-wise outlier 174

detection and manual inspection of the MDS plot. Subjects that failed to follow population 175

homogeneity were discarded. Phasing and imputation were performed using the Michigan 176

- Imputation Server 2 (Das S., et al., 2016) with the 1000 Genomes Project phase 3 dataset. This 177
- platform uses Eagle v2.4 to estimate haplotype phase and Minimac4 for imputation using a 178
- 179 specific reference panel (HRC or 1000 Genomes). SNPs with R2 < 0.3 and minor allele
- frequency (MAF) < 0.05 were excluded. 180
- 181

## 182 2.5 Statistical Analysis and Annotation

The filtered SNPs were analysed for binary traits using the PLINK --assoc command, which 183

employs a chi-squared test to identify SNPs significantly associated with the phenotype of 184

interest. Quality and association results were visualized through QQ plots and Manhattan plots. 185

- 186 Following this, SNP results were functionally annotated using Annovar to identify known and
- novel variants along with their associated genes. 187
- 188

# 189 3. Results

#### **3.1 Patient enrolment** 190

Total, 257 patients were screened at the psychiatric outpatient department of AIIMS. Out of 191 192 these, 213 patients were enrolled in the study, with the remaining excluded due to age criteria, comorbidities, or refusal of consent. Within the enrolled group, 11 patients were excluded due 193 to unsuccessful sample preparation. 82 patients dropped out during follow-up. Ultimately, 120 194 patients successfully completed all the assessments and medication. Table 2 shows 195 demographic details of the patients enrolled and their response group based on the HAMD 196

scale scores after successful evaluations. 197

Characteristics	Patients N=120			
Gender	<b>Responders</b> N=45	Non-responders N=75		
Male (57)	29	28		
Female (63)	16	47		
Age				
18-40 years (81)	31	50		
>40 years (39)	14	25		

Table 2: Demographic characteristics of the patients who have completed assessment. 198

Among the 120 patients studied, 37.5% were categorized as responders, whereas 62.5% were 199 non-responders. Gender distribution showed that males constituted 47.5% of the total sample, 200 with 24.2% of them being responders and 23.3% non-responders. Conversely, females made 201 202 up 52.5% of the sample, with 13.3% responders and 39.2% non-responders, reflecting a higher prevalence of depression in females. Age-wise, 67.5% of the patients were between 18-40 203 years, with 25.8% responders and 41.7% non-responders, indicating a higher impact of 204 depression in the younger age group. In the older age group (above 40 years), 32.5% of the 205 patients were represented, with 11.7% being responders and 20.8% non-responders. These 206 statistics suggest that depression disproportionately affects younger individuals more 207 significantly. 208

All rights reserved. No reuse allowed without permission.

#### 209 **3.2 QC and Population stratification**

210 Genotyping calls from the raw data of all 120 samples (45 True-Responders, 65 Non-Responders, and 10 Resistant) were generated using Genome Studio 2.0. Out of the total 120 211 individuals, two were removed due to high heterozygosity, and one was removed due to 212 duplicate sampling, resulting in 117 samples being retained for association analysis. SNP call 213 rates for all individuals exceeded 98%. Of the initial 654,027 SNPs, 400,460 remained after 214 filtering based on the aforementioned quality control metrics. Utilizing 1000g phase 3 215 population data, the remaining SNPs were subjected to MDS analysis for the assessment of 216 population structure and identification of outliers. As shown in figure 3, all the 117 samples 217 (labelled as OWN) from our study overlapped with individuals from SAS (South Asian) 218 219 population that is composed of five sub-populations including Sri Lankan Tamils from the UK, Indian Telugu from the UK, Gujrati Indian from Houston, Texas, Punjabi from Lahore and 220 Bengali from Bangladesh; the closest representative of Indian population in 1000 Genome 221 phase 3 dataset. As inspected manually as well as computationally there were no significant 222 outliers among the subjects under study, and all were processed further for imputation and 223 association analysis. 224



225

Figure 3: MDS plot showing the population structure of the 1000 Genome phase 3 data with individuals from different global populations including European (EUR), American (AMR), African (AFR), South Asian (SAS), and East Asian (EAS) along with the data of 117 individuals from this study labelled as OWN.

3.3 Phasing and Imputation: Additional pre-processing steps were performed for
 imputation as recommended on the Michigan Server of Imputation, following which 3,82,562
 SNPs and 117 individuals passed all the filters and QC. These SNPs were then subjected to
 imputation using all the populations in the 1000 Genome phase 3 data. Variants with R2 score
 < 0.3 and MAF < 0.05 were filtered out, retaining 67,78,587 imputed SNPs with an average</li>
 genotype calling rate of 1.0.

236

## 237 **3.4** SNPs associated with ITR

perpetuity. All rights reserved. No reuse allowed without permission.

Of the total 117 individuals, 73 belonged to the non-responder (non-responders to monotherapy 238 + those on multi-antidepressant treatment due to non-response to monotherapy) groups and 44 239 belonged to the responder (responders to monotherapy) group. Association based on binary 240 (Case/Control) trait was performed using --assoc option in PLINK v1.7. A Quantile-Quantile 241 Plot was utilized to assess the quality of the data used for association based on Genomic 242 inflation estimate: lambda (based on median chisq) = 1.0321, which was well within the 243 acceptable range and represents good quality data, as shown in Figure 4. SNP results were 244 represented in the form of a Manhattan plot (figure 5) and with a p-value cut-off of 1E-05 (1 x 245 10<sup>-5</sup>), a total of 78 significant variants including 12 lead SNPs were identified, suggestive of a 246 significant association with ITR. Table 3-4 lists the details of the 12 lead SNPs identified 247 suggestive of an association with ITR. Complete list of 78 significant variants is provided in 248 the supplementary file S1. 249



- 250 Figure 4: QQ (Quantile-Quantile) plot of Non-Responder vs Responder comparison showing
- the quality of the data with Genomic Inflation rate Estimate: Lambda = 1.0321, representing
- 252 high-quality data.



253 Figure 5: Manhattan plot demonstrating the relationship between SNPs and non-responders,

highlighting some of the lead SNPs (rsIDs) with  $pval < 1 \ge 10^{-5}$ . The green horizontal line at

(P = 1E-05) represents the genome-wide significance criterion. Red line represents p-value

256 cut-off of 5E-08.

Sno	CHR	POS	SNPID	P-value	Minor Allele	Major Allele	Frequency of Minor Allele in Cases	Frequency of Minor Allele in Controls	Odds Ratio	Asian Population Frequency
1	17	12569992	17:12569992:T:C	2.96E-07	с	т	0.1575	0.4659	0.2144	T=0.7148; C=0.2852
2	13	80651301	13:80651301:G:A	4.18E-07	А	G	0.2397	0.5682	0.2396	G=0.66; A=0.34
3	15	58359744	15:58359744:C:CACAA	5.62E-07	CACAA	С	0.03425	0.25	0.1064	ACA=1.00; ACAAACA=0.00
4	9	33653459	9:33653459:G:A	3.42E-06	А	G	0.08904	0.3295	0.1989	G=0.85; A=0.15
5	9	127457711	9:127457711:G:C	4.50E-06	G	С	0.3288	0.6364	0.2799	G=0.94; C=0.06
6	3	107162120	3:107162120:G:A	5.93E-06	А	G	0.2055	0.4886	0.2706	G=0.64; A=0.36
7	7	46940824	7:46940824:T:C	6.33E-06	с	т	0.05479	0.2614	0.1638	T=0.8554; C=0.1446
8	1	245020277	1:245020277:C:G	7.49E-06	с	G	0.06849	0.2841	0.1853	C=0.15; G=0.85
9	8	100440707	8:100440707:C:T	8.30E-06	т	с	0.3699	0.6705	0.2885	C=0.4960; T=0.5040
10	7	101098969	7:101098969:G:A	8.39E-06	А	G	0.5959	0.2955	3.516	G=0.48; A=0.52
11	19	57422202	19:57422202:A:G	8.80E-06	G	А	0.3836	0.1136	4.853	A=0.631; G=0.369
12	1	157733448	1:157733448:T:A	9.79E-06	т	А	0.3288	0.625	0.2939	T=0.38; A=0.62

#### Table 3: List of SNPs significantly associated with ITR in depression patients 257

Sno	CHR	rsID	Туре	Nearest Coding Gene	Nearest Coding Gene Name
1	17	rs4791503	LINC00670 : Intron Variant	MYOCD	myocardin
2	13	rs1176317	Intergenic	SPRY2	sprouty RTK signaling antagonist 2
3	15	rs1261660572	Intergenic	ALDH1A2; LIPC	aldehyde dehydrogenase 1 family member A2; Lipase C
4	9	rs855549	Intergenic	ANKRD18B	ankyrin repeat domain 18B
5	9	rs2243898	LRSAM1 : Intron Variant	LRSAM1	leucine rich repeat and sterile alpha motif containing 1
6	3	rs116643249	LINC00882(ncRNA) : Intron Variant	CCDC54	coiled-coil domain containing 54
7	7	rs11767105	Intergenic	TNS3	tensin 3
8	1	rs901664	EFCAB2 : Intron Variant	EFCAB2	EF-hand calcium binding domain 2
9	8	rs10107200	LOC105375670 : Intron Variant	ANKRD46	ankyrin repeat domain 46
10	7	rs4489253	TRIM56:1000B Downstream Variant	TRIM56	tripartite motif containing 56
11	19	rs10853894	ZNF17 : 500B Downstream Variant	ZNF17	zinc finger protein 17
12	1	rs10430455	Intergenic	FCRL2	Fc receptor like 2

Table 4: List of nearest genes of the SNPs significantly associated with ITR in depression 258 patients 259

260

perpetuity. All rights reserved. No reuse allowed without permission.

The association analysis of single nucleotide polymorphisms (SNPs) identified several genetic 261 variants significantly associated with antidepressant treatment response. Among the most 262 notable findings, rs4791503 on chromosome 17 exhibited a highly significant p-value of 263  $2.96 \times 10^{-7}$ . The minor allele (C) was observed at a frequency of 0.1575 in cases compared to 264 0.4659 in controls, resulting in an odds ratio of 0.2144. This SNP, an intron variant within the 265 LINC00670 gene, is situated near the MYOCD gene, which encodes myocardin, a critical 266 regulator of smooth muscle gene expression. Another significant SNP, rs1176317 on 267 chromosome 13, displayed a p-value of  $4.18 \times 10^{-7}$ . Here, the minor allele (A) was present in 268 23.97% of cases and 56.82% of controls, yielding an odds ratio of 0.2396. This variant is 269 adjacent to the SPRY2 gene, known for its role in modulating receptor tyrosine kinase signaling 270 pathways. The SNP rs1261660572 on chromosome 15, with a p-value of  $5.62 \times 10^{-7}$ , showed 271 the minor allele (CACAA) frequency to be 0.03425 in cases versus 0.25 in controls, leading to 272 273 an odds ratio of 0.1064. This SNP is located upstream of the ALDH1A2 gene, which is involved 274 in retinoic acid biosynthesis.

Further significant associations were found with rs855549 on chromosome 9 (p-value 275  $3.42 \times 10^{-6}$ ), rs2243898 on chromosome 9 (p-value  $4.50 \times 10^{-6}$ ), and rs116643249 on 276 chromosome 3 (p-value  $5.93 \times 10^{-6}$ ). These SNPs are linked to the *ANKRD18B*, *LRSAM1*, and 277 CCDC54 genes, respectively, all of which play essential roles in protein interactions and 278 signalling pathways. Additionally, the SNPs rs4489253 on chromosome 7 (p-value  $8.39 \times 10^{-6}$ ) 279 and rs10853894 on chromosome 19 (p-value  $8.80 \times 10^{-6}$ ) demonstrated the highest odds ratios 280 of 3.516 and 4.853, respectively, indicating strong associations with the treatment response. 281 These variants are situated near the TRIM56 and ZNF17 genes, involved in ubiquitination and 282 transcription regulation, respectively. These findings underscore the potential genetic markers 283 284 that can predict antidepressant treatment response. The identified genes are integral to various biological processes, including gene regulation, signal transduction, and cellular metabolism, 285 286 thereby contributing to the observed variability in treatment response among individuals.

## 287 4. Discussion and limitations

Our study represents one of the pioneering GWAS investigations into inadequate drug response 288

in depression within the Indian population, utilizing the Illumina Infinium SNP-array platform. 289 The objective was to identify key genetic variations contributing to variability in treatment 290 response. Subjects were carefully selected based on thorough clinical assessments. 291

292 Our study has certain limitations, primarily due to the moderate sample size, which is smaller than typical genome-wide association studies (GWAS). The vast genetic diversity within 293 India's large population adds complexity, as the diverse genetic backgrounds and ethnicities 294 across different regions introduce significant variability not fully captured by the SAS sample 295 in the 1000G population dataset. This variability makes it difficult to generalize our findings 296 297 to the entire population and can introduce confounding factors, reducing the study's power to detect significant associations. Additionally, cultural stigma around psychological disorders in 298 India often leads to underreporting and a lack of formal diagnoses, affecting the quality and 299 accuracy of the data. We also witnessed significant dropouts in follow-ups, which is typical in 300 301 longitudinal studies. Despite these shortcomings, our results are intriguing and of clinical significance given the fact that a considerable number of people who die by suicide have a 302 mental health issue. Identifying individuals at risk early on could avoid such disasters through 303 proper counselling and other preventive measures. 304

Our study successfully identified several genetic variants associated with treatment response, 305 underscoring the importance of including diverse populations in genetic research. To our 306 knowledge, this study is one of the first to explore SNP-based heritability of inadequate drug 307

perpetuity. All rights reserved. No reuse allowed without permission.

response in depression among the Indian population. Most previous GWAS studies have 308 focused on American ancestries. Our findings highlight the need for larger, more inclusive 309 studies to understand the genetic underpinnings of depression and its treatment response in 310 diverse populations. This research marks a significant step toward identifying genetic 311 variations that influence drug response in depression, laying the groundwork for future research 312 and the potential development of personalized treatment strategies that consider the genetic 313 diversity of the Indian population. 314

In our study, we identified over 25 significant intergenic variants on chromosome 15, located 315 near the regulatory regions of genes ALDH1A2 and LIPC. ALDH1A2 (Aldehyde 316 Dehydrogenase 1 Family Member A2) encodes an enzyme involved in retinoate signalling, 317 318 ESR-mediated signalling, and cofactor metabolism. LIPC (Lipase C, hepatic type) plays a crucial role in plasma lipoprotein assembly, remodelling, and cholesterol metabolism, with 319 previous studies linking lipoprotein levels to depression and cognitive behaviour (Jia QF et al., 320 2020). Additionally, one significant variant on chromosome 9 was located in the intronic region 321 of the gene LRSAM1, which encodes a ring finger protein involved in intracellular trafficking, 322 antigen processing, signal transduction, cell adhesion, and the adaptive immune response. 323 Mutations in LRSAMI have been linked to neurodegenerative diseases such as Parkinson's 324 disease (Mishra R et al., 2020). 325

We also discovered four significant intronic variants on chromosome 1 associated with the 326 EFCAB2 gene (EF-Hand Calcium Binding Domain 2), which is involved in calcium ion 327 328 binding. Although its function is not yet fully determined, the GENDEP clinical trial suggests its role in neurodevelopment and cognitive function, particularly in axon cargo transport and 329 330 neurotransmitter release (Uher, R., 2009; Ren H et al., 2018). Furthermore, a downstream 331 variant on chromosome 19 (rs10853894) was significantly associated with the ZNF17 gene, a DNA-binding transcription factor implicated in numerous essential cellular processes, 332 including transcriptional regulation, ubiquitin-mediated protein degradation, signal 333 transduction, actin targeting, DNA repair, and cell migration. ZNF proteins have been 334 associated with various neuro-related diseases, including Alzheimer's, schizophrenia, 335 depression, anxiety, trauma, epilepsy, and autism (Bu S et al., 2021). 336

Other notable genes, such as TRIM56, MYOCD, SPRY2, ANKRD18B, CCDC54, TNS3, 337 338 ANKRD46, and FCRL2, were also identified, highlighting their involvement in innate immune response, nervous system development, PDGFR-beta signalling pathway, FGFR2/3 signalling, 339 340 and receptor tyrosine kinase signalling. These findings provide insights into the genetic 341 underpinnings of drug response in depression, suggesting potential targets for personalized treatment strategies. 342

- Notably, none of the identified SNPs, genes, or loci have been previously reported in earlier 343 GWAS studies on depression. This discrepancy can be attributed to the fact that most GWAS 344 research has predominantly focused on populations of American and Caucasian ancestry, with 345 limited studies conducted on the Asian population, particularly the Indian demographic. 346 Despite this, the major functional ontologies of the identified genes such as Immune response, 347 cell signalling, metabolic pathways, and transcriptional activities were found to overlap 348
- significantly with those reported in previous research. 349

## 350 5. Acknowledgments

The authors thank the clinical staff (Psychologists) Praggapti Ghosh, Dr. Pratibha Lamba, 351

- Tanya Bhatia, Geetanjali Arora, and Hafsa Masroor for their contributions to the psychological 352
- assessments. We also acknowledge Saurabh Dubey for his technical support, Shubham Dhiryan 353
- and Komal Kashyap for data entry. 354

## 355 6. Author Contributions

Conceptualization, S.K., N.K. and G.H.; methodology, I.G., S.K., N.K. and G.H.; software,
I.G and S.K.; formal analysis, I.G.; investigation, S.K., G.H.; data curation, I.G., G.H.;
writing—original draft preparation I.G.; writing—review and editing, I.G., S.K., N.K. and
G.H; supervision, S.K., N.K. and G.H; project administration, S.K., N.K. and G.H; funding
acquisition, S.K., N.K.

361

## 362 7. Institutional Review Board Statement

- Institute Ethics Committee of All India Institute of Medical Sciences, New Delhi gave ethical
   approval for this work, file no. IEC-523/05.06.2020, RP-16/2020
- 365

## 366 8. Informed Consent Statement

- 367 Informed consent was obtained from all subjects involved in the study.
- 368

## 369 9. Data Availability Statement

All data produced in the present study are available upon reasonable request to the authors.

371

# 372 10. Conflicts of Interest

- The authors declare no conflict of interest.
- 374

# 375 11. Funding Statement

This research was funded by ICMR to vide project No. 5/4-4/187/M/2020-NCD-II

377

## 378 12. References

- Institute of Health Metrics and Evaluation (2024). Global Health Data Exchange
   (GHDx). <u>https://vizhub.healthdata.org/gbd-results</u> (Accessed 20 November 2024).
- 381
- World Health Organization: WHO. (2023, March 31). Depressive disorder
   (Depression). <u>https://www.who.int/news-room/fact-sheets/detail/depression</u> (Accessed 20
   November 2024).
- 385
- Johnson CF, Maxwell M, Williams B, Dougall N, MacGillivray S. Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. BMJ Med. 2022 Dec 1;1(1):e000017 <u>https://doi.org/10.1136/bmjmed-2021-000017</u>.
- Rafeyan R, Papakostas GI, Jackson WC, et al. Inadequate response to treatment in major depressive disorder: augmentation and adjunctive strategies. *J Clin Psychiatry*. 2020;81(3):OT19037BR3. <u>https://doi.org/10.4088/JCP.OT19037BR3</u>.
- 394

390

- Arvind BA, Gururaj G, Loganathan S, Amudhan S, Varghese M, Benegal V, Rao GN, Kokane AM, B S C, P K D, Ram D, Pathak K, R K LS, Singh LK, Sharma P, Saha PK, C R, Mehta RY, T M S; NMHS collaborators group. Prevalence and socioeconomic impact of depressive disorders in India: multisite population-based cross-sectional study. BMJ Open. 2019 Jun 27;9(6):e027250. <u>https://doi.org/10.1136/bmjopen-2018-027250</u>.
- 401 6. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and 402 meta-analysis. Am J Psychiatry. 2000 Oct;157(10):1552-62.
  403 <u>https://doi.org/10.1176/appi.ajp.157.10.1552</u>.

404		
405	7.	Sforzini, L., Marizzoni, M., Bottanelli, C. et al. Transcriptomic profiles in major depressive
406		disorder: the role of immunometabolic and cell-cycle-related pathways in depression with
407		different levels of inflammation. <i>Mol Psychiatry</i> (2024). <u>https://doi.org/10.1038/s41380-</u>
408		<u>024-02730-w</u>
409	8	Marlene Santos Luís Lima Serafim Carvalho Jorge Mota Pereira Paulo Pimentel
410 411	0.	Dulce Maia Diana Correia M Fátima Barroso S Gomes Agostinho Cruz Rui
412		Medeiros (2023). The Impact of BDNE NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1.
413		MTOR. PTEN. ARC. and SYN1 Genetic Polymorphisms in Antidepressant Treatment
414		Response Phenotypes. International Journal of Molecular Sciences, 24(7):6758-6758.
415		https://doi.org/10.3390/ijms24076758
416		
417	9.	Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., & Poulton, R.
418		(2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT
419		gene. Science, 301(5631), 386-389. https://doi.org/10.1126/science.1083968.
420		
421	10.	Laje G, Perlis RH, Rush AJ, McMahon FJ. Pharmacogenetics studies in STAR*D: strengths,
422		limitations, and results. Psychiatr Serv. 2009 Nov;60(11):1446-57.
423		<u>https://doi.org/10.11/6/app1.ps.60.11.1446</u> .
424 425	11	Des S. Forer I. Schönherr S. Sidere C. Locke A.F. Kwong A. Vrieze S. Chew F.V. Low S.
425	11.	McGue M Schlessinger D Stambolian D Lob PR Jacono WG Swaroon A Scott I L Cucca
420		F Kronenberg F Boehnke M Abecasis GR Fuchsberger C Next-generation genotype
428		imputation service and methods Nature Genetics 48 1284–1287 (2016)
429		implantion service and methods. Plante Generics 10, 1201 (2010)
430	12.	HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960
431		Feb;23(1):56-62. https://doi.org/10.1136/jnnp.23.1.56.
432		
433	13.	Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR,
434		Manji H, McMahon FJ. Association of GRIK4 with outcome of antidepressant treatment in
435		the STAR*D cohort. Am J Psychiatry. 2007 Aug;164(8):1181-8.
436		https://doi.org/10.1176/appi.ajp.2007.06111790.
437		
438	14.	Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamashita M, Hosoi
439		Y, Azuma J, Kinoshita T, Serretti A. Effect of 5-HT1A gene polymorphisms on
440		antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr
441		Genet. 2009 Jan 5;150B(1):115-23. <u>https://doi.org/10.1002/ajmg.b.30783</u> .
442	1.7	
443	15.	villaruerte SIVI, vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M.
444 445		Sort response in depression may be influenced by SNPs in HIKIB and HIKIA. Psychiatr Genet 2000 Dec:10(6):281 01 https://doi.org/10.1007/VDC.0b012c22822c506c
445 116		$\mathbf{O} = \mathbf{O} = $
440 1/17	16	Hong CI Chen TI VI VW Tsai SI Response to fluovetine and serotonin 1A recentor (C-
44/	10.	Trong CJ, Chen TJ, Tu TW, TSat SJ. Response to huozenne and servicinin TA receptor (C-

- 1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 448 449 2006 Jan-Feb;6(1):27-33. https://doi.org/10.1038/sj.tpj.6500340. 450 17. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A
- 451 functional promoter polymorphism with antidepressant response. Int J 452

Neuropsychopharmacol. 2004 Dec;7(4):501-6.

453

https://doi.org/10.1017/S1461145704004699. 454 455 18. Francis J. McMahon, et al. Variation in the Gene Encoding the Serotonin 2A Receptor Is 456 Associated with Outcome of Antidepressant Treatment. The American Journal of Human 457 Genetics 2006, 78(5):804-814. 458 459 19. Uher, R., Huezo-Diaz, P., Perroud, N. et al. Genetic predictors of response to antidepressants 460 461 the GENDEP project. Pharmacogenomics J 9, 225-233 (2009).in https://doi.org/10.1038/tpj.2009.12. 462 463 464 20. Jia QF, Yang HX, Zhuang NN, Yin XY, Zhu ZH, Yuan Y, Yin XL, Wang Y, Cheung EFC, Chan RCK, Hui L. The role of lipoprotein profile in depression and cognitive performance: 465 a network analysis. Sci Rep. 2020 Nov 26;10(1):20704. https://doi.org/10.1038/s41598-466 020-77782-9. 467 468 21. Mishra, R., Amanullah, A., Upadhyay, A., Dhiman, R., Dubey, A. R., Singh, S., Prasad, A., 469 & Mishra, A. (2020). Ubiquitin ligase LRSAM1 suppresses neurodegenerative diseases 470 linked aberrant proteins induced cell death. International Journal of Biochemistry & Cell 471 Biology, 120, 105697. https://doi.org/10.1016/j.biocel.2020.105697. 472 473 22. Ren, H., Fabbri, C., Uher, R. et al. Genes associated with anhedonia: a new analysis in a 474 clinical (GENDEP). Transl Psychiatry 150 475 large trial 8, (2018). https://doi.org/10.1038/s41398-018-0198-3. 476 477 478 23. Bu S, Lv Y, Liu Y, Qiao S, Wang H. Zinc Finger Proteins in Neuro-Related Diseases Neurosci. 2021 Nov 479 Progression. Front 18:15:760567. https://doi/10.3389/fnins.2021.760567. 480 481 482